Chemed Co. (NYSE:CHE – Get Free Report) CEO Kevin J. Mcnamara sold 2,000 shares of the firm’s stock in a transaction dated Monday, November 25th. The stock was sold at an average price of $572.77, for a total value of $1,145,540.00. Following the completion of the transaction, the chief executive officer now owns 101,735 shares of the company’s stock, valued at approximately $58,270,755.95. This represents a 1.93 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink.
Chemed Trading Down 0.4 %
Shares of NYSE CHE opened at $571.31 on Friday. The stock has a market cap of $8.60 billion, a price-to-earnings ratio of 28.87, a P/E/G ratio of 2.43 and a beta of 0.46. Chemed Co. has a 1-year low of $523.33 and a 1-year high of $654.62. The stock’s 50-day moving average is $578.74 and its 200 day moving average is $565.02.
Chemed (NYSE:CHE – Get Free Report) last posted its quarterly earnings results on Tuesday, October 29th. The company reported $5.64 earnings per share (EPS) for the quarter, missing the consensus estimate of $5.76 by ($0.12). Chemed had a return on equity of 27.86% and a net margin of 12.69%. The company had revenue of $606.18 million for the quarter, compared to the consensus estimate of $612.22 million. During the same quarter in the previous year, the business earned $5.32 earnings per share. Chemed’s revenue was up 7.4% compared to the same quarter last year. On average, analysts forecast that Chemed Co. will post 21.43 EPS for the current fiscal year.
Chemed Announces Dividend
Analyst Ratings Changes
CHE has been the topic of several recent analyst reports. StockNews.com cut Chemed from a “buy” rating to a “hold” rating in a report on Friday, November 22nd. Royal Bank of Canada lowered their price target on Chemed from $697.00 to $633.00 and set an “outperform” rating on the stock in a report on Tuesday, November 5th.
Check Out Our Latest Analysis on CHE
Hedge Funds Weigh In On Chemed
Several institutional investors and hedge funds have recently bought and sold shares of the stock. GAMMA Investing LLC grew its position in Chemed by 34.4% during the 2nd quarter. GAMMA Investing LLC now owns 86 shares of the company’s stock worth $47,000 after acquiring an additional 22 shares during the last quarter. EP Wealth Advisors LLC grew its position in shares of Chemed by 1.9% in the 3rd quarter. EP Wealth Advisors LLC now owns 1,354 shares of the company’s stock worth $814,000 after buying an additional 25 shares during the last quarter. Ballentine Partners LLC grew its position in shares of Chemed by 4.1% in the 3rd quarter. Ballentine Partners LLC now owns 655 shares of the company’s stock worth $394,000 after buying an additional 26 shares during the last quarter. Everpar Advisors LLC grew its position in shares of Chemed by 4.9% in the 2nd quarter. Everpar Advisors LLC now owns 580 shares of the company’s stock worth $315,000 after buying an additional 27 shares during the last quarter. Finally, Creative Planning grew its position in shares of Chemed by 2.8% in the 2nd quarter. Creative Planning now owns 1,228 shares of the company’s stock worth $667,000 after buying an additional 34 shares during the last quarter. 95.85% of the stock is currently owned by institutional investors.
About Chemed
Chemed Corporation provides hospice and palliative care services to patients through a network of physicians, registered nurses, home health aides, social workers, clergy, and volunteers primarily in the United States. The company operates in VITAS and Roto-Rooter segments. It offers plumbing, drain cleaning, excavation, water restoration, and other related services to residential and commercial customers through company-owned branches, independent contractors, and franchisees.
See Also
- Five stocks we like better than Chemed
- When to Sell a Stock for Profit or Loss
- Eli Lilly, Pfizer, and AstraZeneca: 2025 Vaccine Makers to Watch
- 3 Fintech Stocks With Good 2021 Prospects
- DICK’S Sporting Goods: The Under-the-Radar Buy-and-Hold Winner
- How to Calculate Return on Investment (ROI)
- 2 Cheap Quantum Computing Stocks to Buy Instead of Chasing IonQ
Receive News & Ratings for Chemed Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Chemed and related companies with MarketBeat.com's FREE daily email newsletter.